サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1356015

世界の代謝疾患治療薬市場：考察と予測 (2029年まで)

Global Metabolic Disorders Drugs Market Insights, Forecast to 2029
出版日: | 発行: QYResearch | ページ情報: 英文 105 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.24円
世界の代謝疾患治療薬市場：考察と予測 (2029年まで)
出版日: 2023年10月05日
発行: QYResearch
ページ情報: 英文 105 Pages
納期: 2～3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、代謝疾患治療薬 (Metabolic Disorders Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • 代謝疾患治療薬の製品概要
  • 市場：タイプ別
    • 世界の代謝疾患治療薬の市場規模成長率：タイプ別, 2018 VS 2022 VS 2029
    • Glycogen Metabolism Disease Drug
    • Lipid Metabolism Disease Drug
    • Amino Acid Metabolism Drug
    • Other
  • 市場：用途別
    • 世界の代謝疾患治療薬の市場規模成長率：用途別, 2018 VS 2022 VS 2029
    • Hospital
    • Retail Pharmacy
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界の代謝疾患治療薬売上予測・予想 2018-2029
  • 世界の代謝疾患治療薬の収益：地域別
    • 世界の代謝疾患治療薬の収益：地域別: 2018 VS 2022 VS 2029
    • 世界の代謝疾患治療薬の収益：地域別 (2018-2023)
    • 世界の代謝疾患治療薬の収益：地域別 (2024-2029)
    • 世界の代謝疾患治療薬の収益市場シェア 地域別 (2018-2029)
  • 世界の代謝疾患治療薬売上予測・予想 2018-2029
  • 世界の代謝疾患治療薬の販売：地域別
    • 世界の代謝疾患治療薬の販売：地域別: 2018 VS 2022 VS 2029
    • 世界の代謝疾患治療薬の販売：地域別 (2018-2023)
    • 世界の代謝疾患治療薬の販売：地域別 (2024-2029)
    • 世界の代謝疾患治療薬の販売市場シェア 地域別 (2018-2029)
  • 米国・カナダ
  • 欧州
  • 中国
  • アジア（中国を除く）
  • 中東, アフリカ ・ラテンアメリカ

第3章 競合：企業別

  • 世界の代謝疾患治療薬の販売：企業別
    • 世界の代謝疾患治療薬の販売：企業別 (2018-2023)
    • 世界の代謝疾患治療薬の販売市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 代謝疾患治療薬 in 2022
  • 世界の代謝疾患治療薬の収益：企業別
    • 世界の代謝疾患治療薬の収益：企業別 (2018-2023)
    • 世界の代謝疾患治療薬の収益市場シェア：企業別 (2018-2023)
    • 世界の上位10・上位5企業： 代謝疾患治療薬の収益 2022
  • 世界の主要企業 代謝疾患治療薬, 業界ランキング, 2021 VS 2022 VS 2023
  • 世界の代謝疾患治療薬の販売価格：企業別
  • 競合情勢の分析
    • 企業の市場集中度 (CR5 and HHI)
    • 世界の代謝疾患治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 世界の主要メーカー 代謝疾患治療薬, 製造拠点分布と本社
  • 世界の主要メーカー 代謝疾患治療薬, 提供製品と用途
  • 世界の主要メーカー 代謝疾患治療薬, 業界参入時期
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界の代謝疾患治療薬の販売：タイプ別
    • 世界の代謝疾患治療薬の販売実績：タイプ別 (2018-2023)
    • 世界の代謝疾患治療薬の販売予測：タイプ別 (2024-2029)
    • 世界の代謝疾患治療薬の販売市場シェア：タイプ別 (2018-2029)
  • 世界の代謝疾患治療薬 収益：タイプ別
    • 世界の代謝疾患治療薬の収益実績：タイプ別 (2018-2023)
    • 世界の代謝疾患治療薬の収益予測：タイプ別 (2024-2029)
    • 世界の代謝疾患治療薬の収益市場シェア：タイプ別 (2018-2029)
  • 世界の代謝疾患治療薬の価格：タイプ別
    • 世界の代謝疾患治療薬の価格：タイプ別 (2018-2023)
    • 世界の代謝疾患治療薬の価格予測：タイプ別 (2024-2029)

第5章 市場規模：用途別

  • 世界の代謝疾患治療薬の販売：用途別
    • 世界の代謝疾患治療薬の販売実績：用途別 (2018-2023)
    • 世界の代謝疾患治療薬の販売予測：用途別 (2024-2029)
    • 世界の代謝疾患治療薬の販売市場シェア：用途別 (2018-2029)
  • 世界の代謝疾患治療薬の収益：用途別
    • 世界の代謝疾患治療薬の収益実績：用途別 (2018-2023)
    • 世界の代謝疾患治療薬の収益予測：用途別 (2024-2029)
    • 世界の代謝疾患治療薬の収益市場シェア：用途別 (2018-2029)
  • 世界の代謝疾患治療薬の価格：用途別
    • 世界の代謝疾患治療薬の価格：用途別 (2018-2023)
    • 世界の代謝疾患治療薬の価格予測：用途別 (2024-2029)

第6章 米国・カナダ

  • 米国・カナダ 代謝疾患治療薬 市場規模：タイプ別
    • 米国・カナダ 代謝疾患治療薬の販売：タイプ別 (2018-2029)
    • 米国・カナダ 代謝疾患治療薬 収益：タイプ別 (2018-2029)
  • 米国・カナダ 代謝疾患治療薬 市場規模：用途別
    • 米国・カナダ 代謝疾患治療薬の販売：用途別 (2018-2029)
    • 米国・カナダ 代謝疾患治療薬の収益：用途別 (2018-2029)
  • 米国・カナダ 代謝疾患治療薬 市場規模：国別
    • 米国・カナダ 代謝疾患治療薬の収益：国別: 2018 VS 2022 VS 2029
    • 米国・カナダ 代謝疾患治療薬の販売：国別 (2018-2029)
    • 米国・カナダ 代謝疾患治療薬の収益：国別 (2018-2029)
    • US
    • カナダ

第7章 欧州

  • 欧州の代謝疾患治療薬 市場規模：タイプ別
    • 欧州の代謝疾患治療薬の販売：タイプ別 (2018-2029)
    • 欧州の代謝疾患治療薬 収益：タイプ別 (2018-2029)
  • 欧州の代謝疾患治療薬 市場規模：用途別
    • 欧州の代謝疾患治療薬の販売：用途別 (2018-2029)
    • 欧州の代謝疾患治療薬の収益：用途別 (2018-2029)
  • 欧州の代謝疾患治療薬 市場規模：国別
    • 欧州の代謝疾患治療薬の収益：国別: 2018 VS 2022 VS 2029
    • 欧州の代謝疾患治療薬の販売：国別 (2018-2029)
    • 欧州の代謝疾患治療薬の収益：国別 (2018-2029)
    • ドイツ
    • フランス
    • UK
    • イタリア
    • ロシア

第8章 中国

  • 中国の代謝疾患治療薬 市場規模
    • 中国の代謝疾患治療薬 売上 (2018-2029)
    • 中国の代謝疾患治療薬 収益 (2018-2029)
  • 中国の代謝疾患治療薬 市場規模：用途別
    • 中国の代謝疾患治療薬の販売：用途別 (2018-2029)
    • 中国の代謝疾患治療薬の収益：用途別 (2018-2029)

第9章 アジア（中国を除く）

  • アジア地域 代謝疾患治療薬 市場規模：タイプ別
    • アジア地域 代謝疾患治療薬の販売：タイプ別 (2018-2029)
    • アジア地域 代謝疾患治療薬 収益：タイプ別 (2018-2029)
  • アジア地域 代謝疾患治療薬 市場規模：用途別
    • アジア地域 代謝疾患治療薬の販売：用途別 (2018-2029)
    • アジア地域 代謝疾患治療薬の収益：用途別 (2018-2029)
  • アジア地域 代謝疾患治療薬の販売：地域別
    • アジア地域 代謝疾患治療薬の収益：地域別: 2018 VS 2022 VS 2029
    • アジア地域 代謝疾患治療薬の収益：地域別 (2018-2029)
    • アジア地域 代謝疾患治療薬の販売：地域別 (2018-2029)
    • 日本
    • 韓国
    • 台湾
    • 東南アジア
    • インド

第10章 中東, アフリカ ・ラテンアメリカ

  • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬 市場規模：タイプ別
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の販売：タイプ別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬 収益：タイプ別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬 市場規模：用途別
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の販売：用途別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の収益：用途別 (2018-2029)
  • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の販売：国別
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の収益：国別: 2018 VS 2022 VS 2029
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の収益：国別 (2018-2029)
    • 中東, アフリカ ・ラテンアメリカの代謝疾患治療薬の販売：国別 (2018-2029)
    • ブラジル
    • メキシコ
    • トルコ
    • イスラエル
    • 湾岸協力理事会諸国

第11章 企業プロファイル

  • Merck
  • Novartis
  • Takeda Pharmaceutical
  • Astra Zeneca
  • Boehringer Ingelheim
  • KOWA
  • Kythera
  • Fuji yakuhin
  • LG Life Science
  • Metsubishi Tanabe Pharma

第12章 業界チェーンと販売チャネルの分析

  • 代謝疾患治療薬 業界チェーン分析
  • 代謝疾患治療薬 主要原材料
    • 主要原材料
    • 原材料の主要サプライヤー
  • 代謝疾患治療薬 生産形態とプロセス
  • 代謝疾患治療薬 販売およびマーケティング
    • 代謝疾患治療薬 販売チャネル
    • 代謝疾患治療薬 卸業者
  • 代謝疾患治療薬 顧客

第13章 市場動向

  • 代謝疾患治療薬 業界動向
  • 代謝疾患治療薬 市場の促進要因
  • 代謝疾患治療薬 市場の課題
  • 代謝疾患治療薬 市場の抑制要因

第14章 主な調査結果 世界の代謝疾患治療薬の主な市場調査結果

第15章 付録

図表

List of Tables

  • Table 1. Global Metabolic Disorders Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 2. Major Manufacturers of Glycogen Metabolism Disease Drug
  • Table 3. Major Manufacturers of Lipid Metabolism Disease Drug
  • Table 4. Major Manufacturers of Amino Acid Metabolism Drug
  • Table 5. Major Manufacturers of Other
  • Table 6. Global Metabolic Disorders Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Table 7. Global Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 8. Global Metabolic Disorders Drugs Revenue by Region (2018-2023) & (US$ Million)
  • Table 9. Global Metabolic Disorders Drugs Revenue by Region (2024-2029) & (US$ Million)
  • Table 10. Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2023)
  • Table 11. Global Metabolic Disorders Drugs Revenue Market Share by Region (2024-2029)
  • Table 12. Global Metabolic Disorders Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 13. Global Metabolic Disorders Drugs Sales by Region (2018-2023) & (K Units)
  • Table 14. Global Metabolic Disorders Drugs Sales by Region (2024-2029) & (K Units)
  • Table 15. Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2023)
  • Table 16. Global Metabolic Disorders Drugs Sales Market Share by Region (2024-2029)
  • Table 17. Global Metabolic Disorders Drugs Sales by Manufacturers (2018-2023) & (K Units)
  • Table 18. Global Metabolic Disorders Drugs Sales Share by Manufacturers (2018-2023)
  • Table 19. Global Metabolic Disorders Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
  • Table 20. Global Metabolic Disorders Drugs Revenue Share by Manufacturers (2018-2023)
  • Table 21. Global Key Players of Metabolic Disorders Drugs, Industry Ranking, 2021 VS 2022 VS 2023
  • Table 22. Metabolic Disorders Drugs Price by Manufacturers 2018-2023 (USD/Unit)
  • Table 23. Global Metabolic Disorders Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 24. Global Metabolic Disorders Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Drugs as of 2022)
  • Table 25. Global Key Manufacturers of Metabolic Disorders Drugs, Manufacturing Base Distribution and Headquarters
  • Table 26. Global Key Manufacturers of Metabolic Disorders Drugs, Product Offered and Application
  • Table 27. Global Key Manufacturers of Metabolic Disorders Drugs, Date of Enter into This Industry
  • Table 28. Mergers & Acquisitions, Expansion Plans
  • Table 29. Global Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
  • Table 30. Global Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
  • Table 31. Global Metabolic Disorders Drugs Sales Share by Type (2018-2023)
  • Table 32. Global Metabolic Disorders Drugs Sales Share by Type (2024-2029)
  • Table 33. Global Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 34. Global Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 35. Global Metabolic Disorders Drugs Revenue Share by Type (2018-2023)
  • Table 36. Global Metabolic Disorders Drugs Revenue Share by Type (2024-2029)
  • Table 37. Metabolic Disorders Drugs Price by Type (2018-2023) & (USD/Unit)
  • Table 38. Global Metabolic Disorders Drugs Price Forecast by Type (2024-2029) & (USD/Unit)
  • Table 39. Global Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
  • Table 40. Global Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
  • Table 41. Global Metabolic Disorders Drugs Sales Share by Application (2018-2023)
  • Table 42. Global Metabolic Disorders Drugs Sales Share by Application (2024-2029)
  • Table 43. Global Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 44. Global Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 45. Global Metabolic Disorders Drugs Revenue Share by Application (2018-2023)
  • Table 46. Global Metabolic Disorders Drugs Revenue Share by Application (2024-2029)
  • Table 47. Metabolic Disorders Drugs Price by Application (2018-2023) & (USD/Unit)
  • Table 48. Global Metabolic Disorders Drugs Price Forecast by Application (2024-2029) & (USD/Unit)
  • Table 49. US & Canada Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
  • Table 50. US & Canada Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
  • Table 51. US & Canada Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 52. US & Canada Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 53. US & Canada Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
  • Table 54. US & Canada Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
  • Table 55. US & Canada Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 56. US & Canada Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 57. US & Canada Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 58. US & Canada Metabolic Disorders Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 59. US & Canada Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 60. US & Canada Metabolic Disorders Drugs Sales by Country (2018-2023) & (K Units)
  • Table 61. US & Canada Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
  • Table 62. Europe Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
  • Table 63. Europe Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
  • Table 64. Europe Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 65. Europe Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 66. Europe Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
  • Table 67. Europe Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
  • Table 68. Europe Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 69. Europe Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 70. Europe Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 71. Europe Metabolic Disorders Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 72. Europe Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 73. Europe Metabolic Disorders Drugs Sales by Country (2018-2023) & (K Units)
  • Table 74. Europe Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
  • Table 75. China Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
  • Table 76. China Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
  • Table 77. China Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 78. China Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 79. China Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
  • Table 80. China Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
  • Table 81. China Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 82. China Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 83. Asia Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
  • Table 84. Asia Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
  • Table 85. Asia Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 86. Asia Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 87. Asia Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
  • Table 88. Asia Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
  • Table 89. Asia Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 90. Asia Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 91. Asia Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 92. Asia Metabolic Disorders Drugs Revenue by Region (2018-2023) & (US$ Million)
  • Table 93. Asia Metabolic Disorders Drugs Revenue by Region (2024-2029) & (US$ Million)
  • Table 94. Asia Metabolic Disorders Drugs Sales by Region (2018-2023) & (K Units)
  • Table 95. Asia Metabolic Disorders Drugs Sales by Region (2024-2029) & (K Units)
  • Table 96. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
  • Table 97. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
  • Table 98. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
  • Table 99. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
  • Table 100. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
  • Table 101. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
  • Table 102. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
  • Table 103. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
  • Table 104. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
  • Table 105. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country (2018-2023) & (US$ Million)
  • Table 106. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
  • Table 107. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country (2018-2023) & (K Units)
  • Table 108. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
  • Table 109. Merck Company Information
  • Table 110. Merck Description and Major Businesses
  • Table 111. Merck Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 112. Merck Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 113. Merck Recent Developments
  • Table 114. Novartis Company Information
  • Table 115. Novartis Description and Major Businesses
  • Table 116. Novartis Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 117. Novartis Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 118. Novartis Recent Developments
  • Table 119. Takeda Pharmaceutical Company Information
  • Table 120. Takeda Pharmaceutical Description and Major Businesses
  • Table 121. Takeda Pharmaceutical Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 122. Takeda Pharmaceutical Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 123. Takeda Pharmaceutical Recent Developments
  • Table 124. Astra Zeneca Company Information
  • Table 125. Astra Zeneca Description and Major Businesses
  • Table 126. Astra Zeneca Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 127. Astra Zeneca Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 128. Astra Zeneca Recent Developments
  • Table 129. Boehringer Ingelheim Company Information
  • Table 130. Boehringer Ingelheim Description and Major Businesses
  • Table 131. Boehringer Ingelheim Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 132. Boehringer Ingelheim Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 133. Boehringer Ingelheim Recent Developments
  • Table 134. KOWA Company Information
  • Table 135. KOWA Description and Major Businesses
  • Table 136. KOWA Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 137. KOWA Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 138. KOWA Recent Developments
  • Table 139. Kythera Company Information
  • Table 140. Kythera Description and Major Businesses
  • Table 141. Kythera Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 142. Kythera Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 143. Kythera Recent Developments
  • Table 144. Fuji yakuhin Company Information
  • Table 145. Fuji yakuhin Description and Major Businesses
  • Table 146. Fuji yakuhin Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 147. Fuji yakuhin Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 148. Fuji yakuhin Recent Developments
  • Table 149. LG Life Science Company Information
  • Table 150. LG Life Science Description and Major Businesses
  • Table 151. LG Life Science Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 152. LG Life Science Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 153. LG Life Science Recent Developments
  • Table 154. Metsubishi Tanabe Pharma Company Information
  • Table 155. Metsubishi Tanabe Pharma Description and Major Businesses
  • Table 156. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
  • Table 157. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 158. Metsubishi Tanabe Pharma Recent Developments
  • Table 159. Key Raw Materials Lists
  • Table 160. Raw Materials Key Suppliers Lists
  • Table 161. Metabolic Disorders Drugs Distributors List
  • Table 162. Metabolic Disorders Drugs Customers List
  • Table 163. Metabolic Disorders Drugs Market Trends
  • Table 164. Metabolic Disorders Drugs Market Drivers
  • Table 165. Metabolic Disorders Drugs Market Challenges
  • Table 166. Metabolic Disorders Drugs Market Restraints
  • Table 167. Research Programs/Design for This Report
  • Table 168. Key Data Information from Secondary Sources
  • Table 169. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Metabolic Disorders Drugs Product Picture
  • Figure 2. Global Metabolic Disorders Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 3. Global Metabolic Disorders Drugs Market Share by Type in 2022 & 2029
  • Figure 4. Glycogen Metabolism Disease Drug Product Picture
  • Figure 5. Lipid Metabolism Disease Drug Product Picture
  • Figure 6. Amino Acid Metabolism Drug Product Picture
  • Figure 7. Other Product Picture
  • Figure 8. Global Metabolic Disorders Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
  • Figure 9. Global Metabolic Disorders Drugs Market Share by Application in 2022 & 2029
  • Figure 10. Hospital
  • Figure 11. Retail Pharmacy
  • Figure 12. Metabolic Disorders Drugs Report Years Considered
  • Figure 13. Global Metabolic Disorders Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
  • Figure 14. Global Metabolic Disorders Drugs Revenue 2018-2029 (US$ Million)
  • Figure 15. Global Metabolic Disorders Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
  • Figure 16. Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2029)
  • Figure 17. Global Metabolic Disorders Drugs Sales 2018-2029 ((K Units)
  • Figure 18. Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2029)
  • Figure 19. US & Canada Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 20. US & Canada Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 21. Europe Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 22. Europe Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 23. China Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 24. China Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 25. Asia (excluding China) Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 26. Asia (excluding China) Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 27. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
  • Figure 28. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
  • Figure 29. The Metabolic Disorders Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
  • Figure 30. The Top 5 and 10 Largest Manufacturers of Metabolic Disorders Drugs in the World: Market Share by Metabolic Disorders Drugs Revenue in 2022
  • Figure 31. Global Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
  • Figure 32. Global Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • Figure 33. Global Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • Figure 34. Global Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • Figure 35. Global Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • Figure 36. US & Canada Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • Figure 37. US & Canada Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • Figure 38. US & Canada Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • Figure 39. US & Canada Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • Figure 40. US & Canada Metabolic Disorders Drugs Revenue Share by Country (2018-2029)
  • Figure 41. US & Canada Metabolic Disorders Drugs Sales Share by Country (2018-2029)
  • Figure 42. U.S. Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 43. Canada Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 44. Europe Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • Figure 45. Europe Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • Figure 46. Europe Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • Figure 47. Europe Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • Figure 48. Europe Metabolic Disorders Drugs Revenue Share by Country (2018-2029)
  • Figure 49. Europe Metabolic Disorders Drugs Sales Share by Country (2018-2029)
  • Figure 50. Germany Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 51. France Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 52. UK Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 53. Italy Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 54. Russia Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 55. China Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • Figure 56. China Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • Figure 57. China Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • Figure 58. China Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • Figure 59. Asia Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • Figure 60. Asia Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • Figure 61. Asia Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • Figure 62. Asia Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • Figure 63. Asia Metabolic Disorders Drugs Revenue Share by Region (2018-2029)
  • Figure 64. Asia Metabolic Disorders Drugs Sales Share by Region (2018-2029)
  • Figure 65. Japan Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 66. South Korea Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 67. China Taiwan Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 68. Southeast Asia Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 69. India Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 70. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • Figure 71. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • Figure 72. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • Figure 73. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • Figure 74. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Share by Country (2018-2029)
  • Figure 75. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales Share by Country (2018-2029)
  • Figure 76. Brazil Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 77. Mexico Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 78. Turkey Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 79. Israel Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 80. GCC Countries Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
  • Figure 81. Metabolic Disorders Drugs Value Chain
  • Figure 82. Metabolic Disorders Drugs Production Process
  • Figure 83. Channels of Distribution
  • Figure 84. Distributors Profiles
  • Figure 85. Bottom-up and Top-down Approaches for This Report
  • Figure 86. Data Triangulation
  • Figure 87. Key Executives Interviewed
目次

This research report focuses on the Metabolic Disorders Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Metabolic Disorders Drugs Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Metabolic Disorders Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
    • 1.2.2 Glycogen Metabolism Disease Drug
    • 1.2.3 Lipid Metabolism Disease Drug
    • 1.2.4 Amino Acid Metabolism Drug
    • 1.2.5 Other
  • 1.3 Market by Application
    • 1.3.1 Global Metabolic Disorders Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
    • 1.3.2 Hospital
    • 1.3.3 Retail Pharmacy
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Executive Summary

  • 2.1 Global Metabolic Disorders Drugs Sales Estimates and Forecasts 2018-2029
  • 2.2 Global Metabolic Disorders Drugs Revenue by Region
    • 2.2.1 Global Metabolic Disorders Drugs Revenue by Region: 2018 VS 2022 VS 2029
    • 2.2.2 Global Metabolic Disorders Drugs Revenue by Region (2018-2023)
    • 2.2.3 Global Metabolic Disorders Drugs Revenue by Region (2024-2029)
    • 2.2.4 Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2029)
  • 2.3 Global Metabolic Disorders Drugs Sales Estimates and Forecasts 2018-2029
  • 2.4 Global Metabolic Disorders Drugs Sales by Region
    • 2.4.1 Global Metabolic Disorders Drugs Sales by Region: 2018 VS 2022 VS 2029
    • 2.4.2 Global Metabolic Disorders Drugs Sales by Region (2018-2023)
    • 2.4.3 Global Metabolic Disorders Drugs Sales by Region (2024-2029)
    • 2.4.4 Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2029)
  • 2.5 US & Canada
  • 2.6 Europe
  • 2.7 China
  • 2.8 Asia (excluding China)
  • 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

  • 3.1 Global Metabolic Disorders Drugs Sales by Manufacturers
    • 3.1.1 Global Metabolic Disorders Drugs Sales by Manufacturers (2018-2023)
    • 3.1.2 Global Metabolic Disorders Drugs Sales Market Share by Manufacturers (2018-2023)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Metabolic Disorders Drugs in 2022
  • 3.2 Global Metabolic Disorders Drugs Revenue by Manufacturers
    • 3.2.1 Global Metabolic Disorders Drugs Revenue by Manufacturers (2018-2023)
    • 3.2.2 Global Metabolic Disorders Drugs Revenue Market Share by Manufacturers (2018-2023)
    • 3.2.3 Global Top 10 and Top 5 Companies by Metabolic Disorders Drugs Revenue in 2022
  • 3.3 Global Key Players of Metabolic Disorders Drugs, Industry Ranking, 2021 VS 2022 VS 2023
  • 3.4 Global Metabolic Disorders Drugs Sales Price by Manufacturers
  • 3.5 Analysis of Competitive Landscape
    • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.5.2 Global Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.6 Global Key Manufacturers of Metabolic Disorders Drugs, Manufacturing Base Distribution and Headquarters
  • 3.7 Global Key Manufacturers of Metabolic Disorders Drugs, Product Offered and Application
  • 3.8 Global Key Manufacturers of Metabolic Disorders Drugs, Date of Enter into This Industry
  • 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Metabolic Disorders Drugs Sales by Type
    • 4.1.1 Global Metabolic Disorders Drugs Historical Sales by Type (2018-2023)
    • 4.1.2 Global Metabolic Disorders Drugs Forecasted Sales by Type (2024-2029)
    • 4.1.3 Global Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
  • 4.2 Global Metabolic Disorders Drugs Revenue by Type
    • 4.2.1 Global Metabolic Disorders Drugs Historical Revenue by Type (2018-2023)
    • 4.2.2 Global Metabolic Disorders Drugs Forecasted Revenue by Type (2024-2029)
    • 4.2.3 Global Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
  • 4.3 Global Metabolic Disorders Drugs Price by Type
    • 4.3.1 Global Metabolic Disorders Drugs Price by Type (2018-2023)
    • 4.3.2 Global Metabolic Disorders Drugs Price Forecast by Type (2024-2029)

5 Market Size by Application

  • 5.1 Global Metabolic Disorders Drugs Sales by Application
    • 5.1.1 Global Metabolic Disorders Drugs Historical Sales by Application (2018-2023)
    • 5.1.2 Global Metabolic Disorders Drugs Forecasted Sales by Application (2024-2029)
    • 5.1.3 Global Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
  • 5.2 Global Metabolic Disorders Drugs Revenue by Application
    • 5.2.1 Global Metabolic Disorders Drugs Historical Revenue by Application (2018-2023)
    • 5.2.2 Global Metabolic Disorders Drugs Forecasted Revenue by Application (2024-2029)
    • 5.2.3 Global Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
  • 5.3 Global Metabolic Disorders Drugs Price by Application
    • 5.3.1 Global Metabolic Disorders Drugs Price by Application (2018-2023)
    • 5.3.2 Global Metabolic Disorders Drugs Price Forecast by Application (2024-2029)

6 US & Canada

  • 6.1 US & Canada Metabolic Disorders Drugs Market Size by Type
    • 6.1.1 US & Canada Metabolic Disorders Drugs Sales by Type (2018-2029)
    • 6.1.2 US & Canada Metabolic Disorders Drugs Revenue by Type (2018-2029)
  • 6.2 US & Canada Metabolic Disorders Drugs Market Size by Application
    • 6.2.1 US & Canada Metabolic Disorders Drugs Sales by Application (2018-2029)
    • 6.2.2 US & Canada Metabolic Disorders Drugs Revenue by Application (2018-2029)
  • 6.3 US & Canada Metabolic Disorders Drugs Market Size by Country
    • 6.3.1 US & Canada Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 6.3.2 US & Canada Metabolic Disorders Drugs Sales by Country (2018-2029)
    • 6.3.3 US & Canada Metabolic Disorders Drugs Revenue by Country (2018-2029)
    • 6.3.4 US
    • 6.3.5 Canada

7 Europe

  • 7.1 Europe Metabolic Disorders Drugs Market Size by Type
    • 7.1.1 Europe Metabolic Disorders Drugs Sales by Type (2018-2029)
    • 7.1.2 Europe Metabolic Disorders Drugs Revenue by Type (2018-2029)
  • 7.2 Europe Metabolic Disorders Drugs Market Size by Application
    • 7.2.1 Europe Metabolic Disorders Drugs Sales by Application (2018-2029)
    • 7.2.2 Europe Metabolic Disorders Drugs Revenue by Application (2018-2029)
  • 7.3 Europe Metabolic Disorders Drugs Market Size by Country
    • 7.3.1 Europe Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 7.3.2 Europe Metabolic Disorders Drugs Sales by Country (2018-2029)
    • 7.3.3 Europe Metabolic Disorders Drugs Revenue by Country (2018-2029)
    • 7.3.4 Germany
    • 7.3.5 France
    • 7.3.6 UK
    • 7.3.7 Italy
    • 7.3.8 Russia

8 China

  • 8.1 China Metabolic Disorders Drugs Market Size
    • 8.1.1 China Metabolic Disorders Drugs Sales (2018-2029)
    • 8.1.2 China Metabolic Disorders Drugs Revenue (2018-2029)
  • 8.2 China Metabolic Disorders Drugs Market Size by Application
    • 8.2.1 China Metabolic Disorders Drugs Sales by Application (2018-2029)
    • 8.2.2 China Metabolic Disorders Drugs Revenue by Application (2018-2029)

9 Asia (excluding China)

  • 9.1 Asia Metabolic Disorders Drugs Market Size by Type
    • 9.1.1 Asia Metabolic Disorders Drugs Sales by Type (2018-2029)
    • 9.1.2 Asia Metabolic Disorders Drugs Revenue by Type (2018-2029)
  • 9.2 Asia Metabolic Disorders Drugs Market Size by Application
    • 9.2.1 Asia Metabolic Disorders Drugs Sales by Application (2018-2029)
    • 9.2.2 Asia Metabolic Disorders Drugs Revenue by Application (2018-2029)
  • 9.3 Asia Metabolic Disorders Drugs Sales by Region
    • 9.3.1 Asia Metabolic Disorders Drugs Revenue by Region: 2018 VS 2022 VS 2029
    • 9.3.2 Asia Metabolic Disorders Drugs Revenue by Region (2018-2029)
    • 9.3.3 Asia Metabolic Disorders Drugs Sales by Region (2018-2029)
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 China Taiwan
    • 9.3.7 Southeast Asia
    • 9.3.8 India

10 Middle East, Africa and Latin America

  • 10.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Market Size by Type
    • 10.1.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Type (2018-2029)
    • 10.1.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Type (2018-2029)
  • 10.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Market Size by Application
    • 10.2.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Application (2018-2029)
    • 10.2.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Application (2018-2029)
  • 10.3 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country
    • 10.3.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029
    • 10.3.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country (2018-2029)
    • 10.3.3 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country (2018-2029)
    • 10.3.4 Brazil
    • 10.3.5 Mexico
    • 10.3.6 Turkey
    • 10.3.7 Israel
    • 10.3.8 GCC Countries

11 Company Profiles

  • 11.1 Merck
    • 11.1.1 Merck Company Information
    • 11.1.2 Merck Overview
    • 11.1.3 Merck Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.1.4 Merck Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Merck Recent Developments
  • 11.2 Novartis
    • 11.2.1 Novartis Company Information
    • 11.2.2 Novartis Overview
    • 11.2.3 Novartis Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.2.4 Novartis Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 Novartis Recent Developments
  • 11.3 Takeda Pharmaceutical
    • 11.3.1 Takeda Pharmaceutical Company Information
    • 11.3.2 Takeda Pharmaceutical Overview
    • 11.3.3 Takeda Pharmaceutical Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.3.4 Takeda Pharmaceutical Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Takeda Pharmaceutical Recent Developments
  • 11.4 Astra Zeneca
    • 11.4.1 Astra Zeneca Company Information
    • 11.4.2 Astra Zeneca Overview
    • 11.4.3 Astra Zeneca Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.4.4 Astra Zeneca Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 Astra Zeneca Recent Developments
  • 11.5 Boehringer Ingelheim
    • 11.5.1 Boehringer Ingelheim Company Information
    • 11.5.2 Boehringer Ingelheim Overview
    • 11.5.3 Boehringer Ingelheim Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.5.4 Boehringer Ingelheim Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Boehringer Ingelheim Recent Developments
  • 11.6 KOWA
    • 11.6.1 KOWA Company Information
    • 11.6.2 KOWA Overview
    • 11.6.3 KOWA Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.6.4 KOWA Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 KOWA Recent Developments
  • 11.7 Kythera
    • 11.7.1 Kythera Company Information
    • 11.7.2 Kythera Overview
    • 11.7.3 Kythera Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.7.4 Kythera Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.7.5 Kythera Recent Developments
  • 11.8 Fuji yakuhin
    • 11.8.1 Fuji yakuhin Company Information
    • 11.8.2 Fuji yakuhin Overview
    • 11.8.3 Fuji yakuhin Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.8.4 Fuji yakuhin Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.8.5 Fuji yakuhin Recent Developments
  • 11.9 LG Life Science
    • 11.9.1 LG Life Science Company Information
    • 11.9.2 LG Life Science Overview
    • 11.9.3 LG Life Science Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.9.4 LG Life Science Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.9.5 LG Life Science Recent Developments
  • 11.10 Metsubishi Tanabe Pharma
    • 11.10.1 Metsubishi Tanabe Pharma Company Information
    • 11.10.2 Metsubishi Tanabe Pharma Overview
    • 11.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
    • 11.10.4 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.10.5 Metsubishi Tanabe Pharma Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Metabolic Disorders Drugs Industry Chain Analysis
  • 12.2 Metabolic Disorders Drugs Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Metabolic Disorders Drugs Production Mode & Process
  • 12.4 Metabolic Disorders Drugs Sales and Marketing
    • 12.4.1 Metabolic Disorders Drugs Sales Channels
    • 12.4.2 Metabolic Disorders Drugs Distributors
  • 12.5 Metabolic Disorders Drugs Customers

13 Market Dynamics

  • 13.1 Metabolic Disorders Drugs Industry Trends
  • 13.2 Metabolic Disorders Drugs Market Drivers
  • 13.3 Metabolic Disorders Drugs Market Challenges
  • 13.4 Metabolic Disorders Drugs Market Restraints

14 Key Findings in The Global Metabolic Disorders Drugs Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer